

Minireview

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer

F Di Fiore^{*,1,2}, R Sesboué¹, P Michel^{1,2}, JC Sabourin^{1,3} and T Frebourg¹

¹Inserm U614, Faculty of Medicine, Institute for Biomedical Research, 22 Boulevard Gambetta, 76183 Rouen, France; ²Digestive Oncology Unit, Department of Hepato-Gastroenterology, Rouen University Hospital, 1 rue de Germont, 76031 Rouen Cedex, France; ³Department of Pathology, Rouen University Hospital, 1 rue de Germont, 76031 Rouen Cedex, France

Since 2004, the clinical impact of monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) on patients with metastatic colorectal cancer (MCRC) has been clearly established. The combination of these biological agents with conventional chemotherapy has led to a significant improvement in response rate, progression-free survival and overall survival in first-line as well as in second- or third-line treatment of MCRC. However, the high variability of response and outcome in MCRC patients treated with these anti-EGFR mAbs has highlighted the need of identifying clinical and/or molecular predictive markers to ensure appropriate use of targeted therapies. The presence of somatic *KRAS* mutations has been clearly identified as a predictive marker of resistance to anti-EGFR in MCRC, and the use of anti-EGFR mAbs is now restricted to patients with no detectable *KRAS* mutation. Several studies have indicated that amplification of *EGFR*, overexpression of the EGFR ligands and inactivation of the anti-oncogene *TP53* are associated with sensitivity to anti-EGFR mAbs, whereas mutations of *BRAF* and *PIK3CA* and loss of *PTEN* expression are associated with resistance. Besides these somatic variations, germline polymorphisms such as those affecting genes involved in the EGFR pathway or within the immunoglobulin receptors may also modulate response to anti-EGFR mAbs. Until now, all these markers are not completely validated and only *KRAS* genotyping is mandatory in routine practice for use of the anti-EGFR mAbs in MCRC.

British Journal of Cancer (2010) **103**, 1765–1772. doi:10.1038/sj.bjc.6606008 www.bjcancer.com

Published online 23 November 2010

© 2010 Cancer Research UK

Keywords: colorectal cancer; EGFR; monoclonal antibodies; predictive marker; *KRAS*

Colorectal cancer (CRC) is the third most common cancer worldwide. Synchronous metastases are estimated to occur in 25% of patients, and ~40–50% of patients with newly diagnosed CRC develop secondary metastases (Meyerhardt and Mayer, 2005). Since 2004, numerous studies have demonstrated the efficiency of monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) ectodomain, such as cetuximab and panitumumab, in patients with metastatic colorectal cancer (MCRC). Cetuximab corresponds to a chimeric mouse human IgG1 mAb, and panitumumab is a fully human IgG2 mAb.

Indeed, several randomised trials conducted in chemorefractory as well as in chemo-naïve MCRC patients have reported significant results for cetuximab and panitumumab monotherapy or chemotherapy-based (CT) regimens (Cunningham *et al*, 2004; Jonker *et al*, 2007; Van Cutsem *et al*, 2007, 2009a; Bokemeyer *et al*, 2009). In a randomised phase II trial including irinotecan-refractory MCRC patients, Cunningham *et al* (2004) reported that cetuximab plus irinotecan significantly improved the response rate and progression-free survival (PFS) when compared with cetuximab alone (22.9 vs 10.8% and 4.1 vs 1.5 months, respectively). Recently, a phase III randomised trial conducted by Van Cutsem *et al* (2009a, b) showed that in chemo-naïve MCRC patients, the addition of anti-EGFR to irinotecan-based CT lead to an 8.2% increase in

the objective response (46.8 vs 38.4%), a 0.9-month increase in the PFS (8.9 vs 8 months) and a 1.3-month increase in the overall survival (OS) (19.9 vs 18.6 months). Although the response to anti-EGFR mAbs observed in some patients has confirmed that EGFR activation is oncogenic, as predicted by cellular and animal models, the molecular mechanisms underlying EGFR activation in colorectal cancer remain obscure and are probably heterogeneous. This situation contrasts with in lung adenocarcinoma in which the key mechanism of EGFR activation underlying sensitivity to EGFR inhibitors corresponds to activating mutations within the EGFR tyrosine kinase domain. Although the use of anti-EGFR mAbs was initially restricted to MCRC patients with a detectable expression of EGFR by immunohistochemistry (IHC), the lack of IHC predictive value and the heterogeneous clinical response have highlighted the need to identify reliable markers predictive of response to anti-EGFR mAbs (Chung *et al*, 2005).

Two types of molecular predictive markers have been investigated. The majority of studies published so far have analysed somatic alterations affecting effectors of EGFR pathways, such as the receptor–ligand complex, the RAS–RAF–mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K)–Akt–PTEN transduction cascades and p53 (Moroni *et al*, 2005; Lièvre *et al*, 2006, 2008; Benvenuti *et al*, 2007; Di Fiore *et al*, 2007; Frattini *et al*, 2007; Khambata-Ford *et al*, 2007; Amado *et al*, 2008; De Roock *et al*, 2008; Di Nicolantonio *et al*, 2008; Oden-Gangloff *et al*, 2009; Van Cutsem *et al*, 2009a). Studies have indicated that amplification of EGFR and overexpression of the EGFR ligands are associated to sensitivity to anti-EGFR mAbs,

*Correspondence: Dr F Di Fiore; E-mail: frederic.di-fiore@chu-rouen.fr
Received 28 June 2010; revised 24 September 2010; accepted 22 October 2010; published online 23 November 2010

whereas mutations of BRAF, of PIK3CA and loss of PTEN expression are associated with resistance (Figure 1, bottom panel). The second type of predictive markers investigated are germline polymorphisms of genes involved in the EGFR pathway (Khambata-Ford *et al*, 2007; Graziano *et al*, 2008; Garm Spindler *et al*, 2009) or within the immunoglobulin receptors, considering the potential role of antibody-dependent cellular cytotoxicity (ADCC) in the action of anti-EGFR mAbs (Zhang *et al*, 2007; Bibeau *et al*, 2009). At the present time, the only molecular marker predictive of the response to anti-EGFR mAbs, which has been unambiguously validated in MCRC by numerous studies, is the somatic mutation of KRAS as a marker of resistance to anti-EGFR (Lièvre *et al*, 2006, 2008; Di Fiore *et al*, 2007; Frattini *et al*, 2007; Amado *et al*, 2008; De Roock *et al*, 2008; Van Cutsem *et al*, 2009a). This has led to systematic KRAS genotyping in MCRC patients and to the restriction of anti-EGFR mAbs to patients with no detectable KRAS mutation. Nevertheless, KRAS mutations are obviously not the only determinants of the clinical response to anti-EGFR.

OVERVIEW OF THE EGFR PATHWAY

The receptors of EGF are composed of homodimers or heterodimers of four related glycoproteins: HER1 (or EGFR), HER2 (or Erbb2), HER3 and HER4 (Figure 1, top panel). These receptors are composed of an extracellular ligand-binding domain, a transmembrane segment and an intracellular protein tyrosine kinase domain. In a normal cell, activation of EGFR is induced by the binding of the ligands to the ectodomain (Ciardiello and Tortora, 2001, 2008). Approximately ten ligands can activate the

EGFR pathway. The ligands for HER1/EGFR are EGF, TGF- α , HB-EGF, amphiregulin, epiregulin and VGF; heregulins are the ligands of Her-3; NRG2, NRG3, heregulins and β -cellulin are the ligands of ErbB-4, and Her-2 is an orphan receptor. Binding of the ligands will induce EGFR homodimerisation (EGFR-EGFR) or heterodimerisation (EGFR-HER2; EGFR-HER3 or EGFR-HER4) and then ATP-dependent phosphorylation of tyrosine residues located within the intracellular domain. The phosphorylated EGFR will then lead to the activation of the RAS-RAF-MAPK kinase and the PI3K-Akt transduction cascades. The RAS-RAF-MAPK kinase is the major downstream signalling route of the EGFR pathway and it controls cell-cycle progression, differentiation, survival and in particular, the G1/S-phase transition (Ciardiello and Tortora, 2008). The RAS proteins are members of a large superfamily of guanine guanosine-5'-triphosphate (GTP) and guanine guanosine-5'-diphosphate (GDP)-binding proteins. In normal cells, EGFR activates RAS by stimulating its binding to GTP. RAF will then be activated and will phosphorylate the MAP2K1 and MAP2K2 kinases. The p110 subunit of PI3K encoded by the PIK3CA oncogene is activated by RAS proteins. The PI3K-Akt pathway, which is negatively regulated by the PTEN protein, activates antiapoptotic and survival signals (Figure 1, top panel).

In cancerous cells, EGFR pathway activation results in cell proliferation, inhibition of apoptosis, activation of invasion, metastasis and tumour neovascularisation (Ciardiello and Tortora, 2001, 2008; Cohen *et al*, 2005). The main mechanism of EGFR activation, so far characterised in CRC, corresponds to the somatic mutation of the KRAS proto-oncogene. Somatic mutations of KRAS are detected in ~30–40% of CRCs (Andreyev *et al*, 2001). These activating mutations are missense mutations that introduce amino-acid substitutions mainly at positions 12, 13 and 61. Activating mutations of other EGFR pathway effectors have also been described. In CRC, mutations of BRAF and PI3K genes are detected in ~5–10% and 6–13% of the tumours, respectively (Moroni *et al*, 2005; Lièvre *et al*, 2006; Di Nicolantonio *et al*, 2008; Laurent-Puig *et al*, 2009; Prenen *et al*, 2009; Sartore-Bianchi *et al*, 2009). Somatic mutations of KRAS and BRAF are mutually exclusive.

KRAS MUTATION: A VALIDATED PREDICTIVE MARKER OF RESISTANCE TO ANTI-EGFR

Since 2004, the predictive value of somatic KRAS mutation, in terms of resistance to anti-EGFR mAbs, has been established by numerous studies. These studies (see Table 1), mainly focusing on mutations of codons 12 and 13, and more recently on codon 61, have been based on molecular analyses of tumour-extracted DNAs from patients included in retrospective studies, as well as in prospective randomised trials (Lièvre *et al*, 2006, 2008; Benvenuti *et al*, 2007; Di Fiore *et al*, 2007; Frattini *et al*, 2007; Amado *et al*, 2008; De Roock *et al*, 2008; Bokemeyer *et al*, 2009; Loupakis *et al*, 2009a; Van Cutsem *et al*, 2009a). The first line of evidence that KRAS mutation was a strong predictor of resistance to anti-EGFR mAbs was the observation that in chemorefractory patients treated with cetuximab-based CT, <2% of patients with detectable KRAS mutation exhibited an objective response, whereas ~40% of patients with no detectable KRAS mutation showed a clinical response (Lièvre *et al*, 2006, 2008; Benvenuti *et al*, 2007; Di Fiore *et al*, 2007, 2008a,b; Frattini *et al*, 2007; De Roock *et al*, 2008; Loupakis *et al*, 2009a). The impact of KRAS status in response to anti-EGFR mAbs was also documented by trials in chemorefractory patients comparing cetuximab or panitumumab monotherapy vs best supportive care, with an increase in the response rate in patients with no KRAS mutation from 8 to 12.8% and from 10 to 17%, respectively (Karapetis *et al*, 2008).

In chemo-naïve patients with no detectable KRAS mutation, the addition of anti-EGFR antibodies to CT increased the objective response from approximately 46 to 60% when compared with CT




Figure 1 An overview of the EGFR pathway and its main downstream effectors (top). Expected outcomes of anti-EGFR (mAb) therapy (bottom): sensitivity (tumour response) when EGFR is activated (gain copy number, ligand overexpression, other unknown mechanisms) and downstream effectors are wild type (left); resistance (tumour development and metastasis) when downstream effectors such as KRAS, BRAF or PI3K are activated or PTEN is inactivated (right).

Table 1 Response rate (OR) and PFS in MCRC patients treated with anti-EGFR mAb-based CT

Regimen(s)	Study	n	Response KRAS WT (%)	P-value	PFS KRAS WT (months)	P-value
<i>Chemonaïve patients: 1st line</i>						
Cmab+FOLFOX vs FOLFOX	Bokemeyer et al (2009, 2010)	315	57.3 vs 34.0	0.0027	8.3 vs 7.2	0.0064
Cmab+FOLFIRI vs FOLFIRI	Van Cutsem et al (2009a, b, 2010)	1063	57.3 vs 39.7	<0.0001	9.9 vs 8.4	<0.0012
Pmab+FOLFOX vs FOLFOX	Douillard et al (2009)	1183	55.0 vs 48.0	NS	9.6 vs 8.0	0.02
<i>Chemorefractory patients: 2nd line</i>						
Pmab + FOLFIRI vs FOLFIRI	Peeters et al (2009)	1186	35 vs 10	<0.01	5.9 vs 3.9	0.004
<i>Chemorefractory patients: ≥2nd line</i>						
Cmab ± CT	Lièvre et al (2006)	30	40.7	—	—	—
Cmab ± CT	Di Fiore et al (2007)	59	27.9	—	5.5	—
Cmab ± CT	Lièvre et al (2008)	114	43.5	—	7.4	—
Cmab ± CT	De Roock et al (2008)	80	45.8	—	7.9	—
Cmab/Pmab ± CT	Benvenuti et al (2007)	48	31.2	—	—	—
<i>Chemorefractory patients: > 3rd line</i>						
Cmab mono vs BSC	Karapetis et al (2008)	394	12.8 vs 0	—	3.7 vs 1.9	<0.001
Pmab mono vs BSC	Amado et al (2008)	427	17 vs 0	—	2.9 vs 1.7	<0.0001

Abbreviations: BSC = best supportive care; CI = confidence interval; Cmab = cetuximab; CT = chemotherapy; EGFR = epidermal growth factor receptor; mAb = monoclonal antibody; MCRC = metastatic colorectal cancer; NS = not significant; OS = overall survival; PFS = progression-free survival; Pmab = panitumumab; WT = wild type.

alone (Douillard *et al*, 2008, 2009; Bokemeyer *et al*, 2009; Van cutsem *et al*, 2009a). Except in the recent COIN randomised trial (Maughan *et al*, 2009), the addition of anti-EGFR mAbs to CT has also been shown to lead to a significant increase in the median PFS when compared with irinotecan- or oxaliplatin-based CT alone in chemonaïve as well as in chemorefractory patients. In contrast, in mutant *KRAS* patients, no clinical benefit was observed from the combination of anti-EGFR plus CT. The effect of *KRAS* status on OS in MCRC patients treated in first line remains debatable, with contradictory results that are mainly explained by the non-standardisation of second- and third-line CT as well as several confounding factors such as treatment crossover and different monitoring methods used in these such randomised trials (Douillard *et al*, 2009; Van Cutsem *et al*, 2009a, b).

OTHER SOMATIC PREDICTIVE MARKERS OF RESPONSE TO ANTI-EGFR

PIK3CA and PTEN alterations

The demonstration that in MCRC patients *KRAS* mutations confer resistance to anti-EGFR has validated the hypothesis that targeting EGFR will be inefficient if activation of the EGFR transduction cascade results from somatic alterations affecting downstream effectors (Figure 1, bottom panel). This led to an investigation of the predictive value of somatic alterations affecting other effectors. In colorectal cancer, activation of the PIK3CA pathway can result either from activating *PIK3CA* mutations or from inactivation of the PTEN protein. Since 2005, the impact of *PIK3CA* mutations on MCRC patients treated with anti-EGFR has been investigated by several studies that have reported a *PIK3CA* mutation frequency ranging from 6 to 13% (Moroni *et al*, 2005; Lièvre *et al*, 2006; Perrone *et al*, 2009; Prenen *et al*, 2009; Sartore-Bianchi *et al*, 2009). In the studies of Moroni *et al* (2005), Lièvre *et al* (2006) and Perrone *et al* (2009), none of the responders to anti-EGFR therapy had a *PIK3CA* mutation, but this association was not statistically significant, given the limited number of patients. In contrast, a significant association between the presence of *PIK3CA* mutation and response to anti-EGFR has been recently reported by Sartore-Bianchi *et al* (2009) in a study including 110 patients treated with anti-EGFR mAbs. A total of 32 (29%) patients had a *KRAS* mutation and 15 (13%) had a *PIK3CA* mutation. When compared

with the unselected population, the response rate to anti-EGFR increased from 20 to 26% in patients with no *KRAS* mutation, to 23% in patients with no *PIK3CA* mutation and to 31% in patients with no *KRAS/PIK3CA* mutations (Sartore-Bianchi *et al*, 2009). Nevertheless, these results were not confirmed by the recent study of Prenen *et al* (2009), in which *PIK3CA* mutations were identified in 5 of 39 (13%) responders vs 18 of 160 (11%) nonresponders ($P=0.781$). These contradictory results highlight the fact that the association between *PIK3CA* mutations and resistance to anti-EGFR is not yet validated.

PTEN exerts an effect as a tumour suppressor by dephosphorylating the plasma membrane lipid second messenger PIP-3 generated by the action of PI3KCA. The loss of *PTEN* function induces an increase in PIP-3 concentration and *PIK3CA* pathway activation. IHC and FISH analyses are the two main methods that have been used to evaluate the *PTEN* status in studies focused on anti-EGFR resistance. However, the molecular mechanisms leading to *PTEN* inactivation are heterogeneous and include genomic deletions, inactivating mutations and promoter hypermethylation, indicating that *PTEN* integrity cannot be explored by a simple method. In a series of 27 MCRC patients, Frattini *et al* (2007) reported that *PTEN* alteration detected by IHC in primary tumours was significantly associated with cetuximab resistance. More recently, Loupakis *et al* (2009b) have analysed by IHC the impact of *PTEN* cytoplasmic staining intensity in 85 primary tumours and 55 related metastases from patients treated with cetuximab plus irinotecan. First, using a specific scoring system for *PTEN* expression, these authors found that IHC staining was concordant in only 27 out of 45 (60%) pairs of assessable primary and related metastases. Second, the results of the *PTEN* IHC performed on the 85 primary tumours did not correlate with the response and PFS, whereas *PTEN* IHC analysis performed on the 55 metastases was significantly associated with response rate and PFS. When the *KRAS* mutational status in the primary tumours and the *PTEN* expression in metastasis were combined, the subgroup of patients with no detectable *KRAS* mutation and positive to *PTEN* had a significantly higher response and longer PFS than patients with *KRAS* mutation and negative to *PTEN*. In patients with no *KRAS* mutation, Laurent-Puig *et al* (2009) found that the absence of *PTEN* expression, detected in 19.9% of patients using another IHC scoring system, was associated with shorter OS in univariate and multivariate analyses. In a series of 72 MCRC patients treated with anti-EGFR mAbs plus CT, Razis *et al* (2008) evaluated the

correlation of *PTEN* gene copy number and sensitivity to anti-EGFR. The absence of *PTEN* gene dosage alteration was significantly associated with response rate, whereas *PTEN* gene deletion was correlated with worse PFS. No significant association was found using *PTEN* IHC expression. All these results clearly indicate that no obvious association has yet been established between *PTEN* alterations and anti-EGFR therapy in MCRC patients. It should also be noted that commercially available anti-*PTEN* antibodies do not always provide reproducible results in IHC. Further studies are needed to determine the most efficient and reproducible methods for *PI3KCA* and *PTEN* analysis in order to clearly evaluate the predictive value of each marker separately or in combination with *KRAS* status.

BRAF mutation

Two studies support that V600E mutation, resulting in strong activation of the BRAF protein downstream to *KRAS*, was associated with shorter PFS and OS in MCRC chemorefractory patients treated with anti-EGFR mAbs (Di Nicolantonio *et al*, 2008; Laurent-Puig *et al*, 2009). Nevertheless, it seems that whatever the treatment, this mutation in MCRC is mainly associated with poor prognosis, which may interfere with its predictive value regardless of anti-EGFR mAbs (Tol *et al*, 2010; Van Cutsem *et al*, 2010).

TP53 mutations

In a normal cell, the p53 protein exerts an effect not only as a guardian of the genome, which is activated when DNA damage occurs, but also as a policeman of oncogenes, which become active when oncogenes are inappropriately activated, thus inducing apoptosis and/or senescence (Efeyan and Serrano, 2007; Halazonetis *et al*, 2008). Alteration of the p53 pathway has been reported to be systematically observed in non-small cell lung cancer with activating *EGFR* mutations, suggesting that p53 inactivation is required to allow expansion of a cell with *EGFR* pathway activation (Mounawar *et al*, 2007). On the other hand, it has been shown that PI3K signalling activates p53-mediated growth suppression, suggesting that p53 exerts an effect as a brake for the activated PI3K transduction cascade (Kim *et al*, 2007). Taken together, these data led us to formulate the hypothesis that activation of the *EGFR* pathway should be oncogenic, and therefore anti-EGFR antibodies should only be efficient in tumours, only if p53 is inactivated. We have recently analysed the impact of *TP53* mutations on 64 MCRC patients treated with cetuximab plus CT (Oden-Gangloff *et al*, 2009). In this series, *TP53* mutations were found in 41 of 64 patients and were significantly associated with controlled disease

($P=0.037$) and higher PFS (20 vs 12 weeks, $P=0.004$). In the subgroup of patients without *KRAS* detectable mutation, we have also found that controlled disease and PFS were significantly improved in *TP53* mutated patients when compared with *TP53* nonmutated patients. These results might be explained not only by the fact that *EGFR* activation is oncogenic only if *TP53* is inactivated, but also by the fact that inactivation of *TP53* could be one of the mechanisms leading to *EGFR* activation. Cellular models and studies on larger MCRC series are necessary to clarify the relationship between *TP53* status and sensitivity to anti-EGFR.

EGFR gene copy number and expression of its ligands

EGFR gene copy number A common mechanism of *EGFR* activation is the increase in the *EGFR* copy number corresponding to the gain of copies or amplification of the chromosome 7 region on which *EGFR* is located. A copy number increase of *EGFR* resulting from chromosome 7 polysomy probably does not have the same biological significance than amplification of the *EGFR* locus. In contrast to breast cancer in which tumour cells exhibit *HER2* amplification in homogeneous regions with a relationship between expression and gene amplification, colorectal cancer is characterised by a heterogeneous *EGFR* gene copy number pattern and, furthermore, no correlation has been established between the *EGFR* copy number and the *EGFR* IHC staining. Based on the results obtained in patients with metastatic breast cancer treated with trastuzumab, in which *ERBB2* amplification correlates with sensitivity to mAb therapy, Moroni *et al* (2005) investigated the impact of the *EGFR* gene copy number, assessed by FISH, on the anti-EGFR mAb response in a series of 30 MCRC patients. This study reported a positive significant association between an increased *EGFR* gene copy number and the response rate to cetuximab or panitumumab. Since 2005, many reports have investigated the relationship between *EGFR* copy number and response to mAb therapy in MCRC, but only five of them restricted the analysis to the subgroup of wild-type *KRAS* patients (Table 2). Although an increase in *EGFR* copy number is significantly associated with mAb therapy response, the results are less obvious in terms of PFS or OS. Cappuzzo *et al* (2008), in a series of 85 chemorefractory patients treated with cetuximab, determined that the best cutoff significantly associated with the response rate and PFS was 2.92 *EGFR* gene copy number per cell. Interestingly, these authors further analysed their population according to the *EGFR* copy number cutoff previously reported by Sartore-Bianchi *et al* (2009) and observed a significant association for response rate but not for PFS. It can be concluded from the different studies

Table 2 Influence of *EGFR* status (gene copy number) on subject response in *KRAS* wild-type MCRC patients treated with anti-EGFR mAb-based CT

Study	N	EGFR cutoff	PFS (months)			OS (months)			Responders CR+PR	Nonresponders SD+PD	P-value
			No	95% CI	P-value	No	95% CI	P-value			
Moroni <i>et al</i> (2005)	20	$\geq 3^a$	—	—	—	—	—	—	6	1	0.001
		< 3	—	—	—	—	—	—	1	12	
Personeni <i>et al</i> (2008)	58	$\geq 2.83^a$	5.5	—	0.25	10	—	0.037	17	10	0.007
		< 2.83	4	—	—	8.3	—	—	8	23	
Laurent-Puig <i>et al</i> (2009)	116	$\geq 2^a$	8.5	7–16	0.28	20	13–NA	0.018	12	5	0.015
		< 2	7	5–8.5	—	14	11–17	—	29	50	
Scartozzi <i>et al</i> (2009)	44	$\geq 2.6^a$	7.7	—	0.04	16	—	0.2	9	6	0.001
		< 2.6	2.9	—	—	9.5	—	—	2	21	
		$\geq 2.12^b$	6.4	—	0.02	10.6	—	0.95	10	18	
		< 2.12	3.1	—	—	10.3	—	—	1	15	
Tol <i>et al</i> (2010)	155	$\geq 3^a$	9.5	6.4–12.3	0.19	21.9	13.4–27.1	0.65	—	—	—
		< 3	10.4	8.6–12.2	—	22	19.2–25.4	—	—	—	

Abbreviations: CI = confidence interval; CISH = chromogenic *in situ* hybridisation; CR = complete response; CT = chemotherapy; EGFR = epidermal growth factor receptor; FISH = fluorescence *in situ* hybridisation; mAb = monoclonal antibody; MCRC = metastatic colorectal cancer; NA = not assessable; OS = overall survival; PFS = progression-free survival; PR = partial response; PD = progressive disease; SD = stable disease. ^aFISH. ^bCISH.

published so far that only a high *EGFR* gene copy number, resulting from gene amplification and observed in a small fraction of patients, is probably predictive of anti-EGFR sensitivity in MCRC patients.

Expression of EGFR ligands Few studies have investigated the predictive role of EGFR ligand expression on anti-EGFR response in MCRC. A transcriptome analysis of 164 CRCs, using a 640 probe set, showed that the EGFR ligands, epiregulin (*EREG*) and amphiregulin (*AREG*), were highly expressed in 25% of the samples (Khambata-Ford *et al*, 2007). In this study, analysis of metastatic frozen samples from a population of 80 MCRC patients treated with cetuximab monotherapy showed that patients with disease control expressed the EGFR ligands at a higher level than nonresponders. Moreover, patients with tumours exhibiting higher *EREG* or *AREG* expression had significantly longer PFS, suggesting that these tumours were EGFR dependent and were therefore particularly sensitive to the inhibition of the ligand–receptor interaction by anti-EGFR mAb (Khambata-Ford *et al*, 2007). In a recent study performed on paraffin-embedded samples in refractory MCRC patients treated with cetuximab and irinotecan, the *KRAS* status and the *EREG* and *AREG* mRNA expression were first determined on 220 primary samples and the results were then validated on a series of 67 patients (Jacobs *et al*, 2009). The mRNA levels of *EREG* and *AREG* significantly correlated with the absence of detectable *KRAS* mutation. When ligand expression level was combined with the *KRAS* status, the median OS was 65 weeks in patients with no detectable *KRAS* mutation and a high *EREG* expression vs 31 weeks ($P=0.01$) in patients without detectable *KRAS* mutation and low *EREG* expression (Jacobs *et al*, 2009).

GERMLINE POLYMORPHISMS ASSOCIATED WITH CLINICAL RESPONSE TO ANTI-EGFR MABS

Three types of germline polymorphisms suspected of modulating the response to anti-EGFR have been investigated. The first corresponds to a CA repeat present within the *EGFR* intron 1, which has been shown to modulate EGFR transcription efficiency, the longer (L) repeats being associated with a reduced transcription when compared with the shorter (S) ones. The second, located within the *EGF* gene, corresponds to a SNP (G > A, rs4444903). In 110 chemorefractory MCRC patients treated with cetuximab–irinotecan, Graziano *et al* (2008) showed that *EGFR* intron-1 variant (S/S vs L/L and L/S) and *EGF61* variant (G/G vs A/A and A/G) were significantly associated with a better OS. Similar results were obtained on *EGF61* genotypes in a study on chemorefractory MCRC patients treated with cetuximab plus irinotecan CT (Garm Spindler *et al*, 2009). In patients with no detectable *KRAS* mutation, homozygous phenotypes (A/A and G/G) were associated with a lower progression rate (19 vs 60%) than *EGF61* A/G patients ($P=0.006$) and a significant increase in OS (17.1 vs 5.9 months). The third type of germline polymorphism investigated, in the context of anti-EGFR therapies in MCRC, corresponds to polymorphic amino-acid substitutions within the receptors of the Fc fragment of the immunoglobulins (Igs). The H131R and V158F variations within the Fc γ RIIa and Fc γ RIIIa have been shown to modify the affinity of the Ig receptors and are therefore predicted to modulate the ADCC in patients receiving anti-EGFR IgG1 mAb. To date, only four studies have found significant association between these polymorphisms and the clinical outcome. In a first study performed in a series of 39 chemorefractory patients treated with cetuximab monotherapy, Zhang *et al* (2007) found that the presence of the *FCGR2A* 131 H allele and of the *FCGR3A* 158 F allele were significantly associated with better PFS; however, these results could not be replicated on a larger series including 130 subjects (Lurje *et al*, 2008). In 64 chemorefractory MCRC patients treated with cetuximab-based CT, Bibeau *et al* (2009) found that

the *FCGR2A* 131 H/H and *FCGR3A* 158 V/V genotypes, predicted to result in a higher affinity of the Ig to the receptor, were significantly associated with better PFS. In this study, analysis of these germline polymorphisms in the subgroup of patients with no detectable *KRAS* mutation showed that the median PFS was 9.6 months in the 131 H/H or 158 V/V patients vs 4.6 months in the subgroup of patients harbouring the other genotypes ($P=0.015$). In contrast, a more recent study (Pander *et al*, 2010), performed on *KRAS* wild-type patients receiving chemotherapy plus cetuximab, showed that subjects homozygous for the *FCGR3A* 158 F allele have a better PFS than those bearing other allelic combinations. Several factors may account for these discrepancies; although ethnic origin is unlikely to be involved, previous treatment regimens and association of irinotecan with cetuximab could modify patients' response. Further studies involving testing integrity of the EGFR pathway are clearly needed to clarify this point.

MUTATIONAL STATUS IN PRIMARY COLORECTAL ADENOCARCINOMAS AND RELATED METASTASES

One of the main subjects of debate is the relevance of *KRAS* genotyping on primary tumours, whereas anti-EGFR mAbs are used to treat a metastatic disease. Indeed, some publications have indicated that concordance of mutational status of *KRAS* and other EGFR downstream effectors between primary and metastases is not absolute. In a series of 48 CRC patients, an overall concordance of 92% was observed between primary tumours and metastases for the presence of mutations within *KRAS* exon 2 and *BRAF* exon 5 (Artale *et al*, 2008); however, in the specific subgroup of patients with *KRAS* mutation, 23% of discordance was observed between the two tumour sites. In a study including 38 MCRCs, Molinari *et al* (2009) reported a concordance for *KRAS* and *BRAF* mutational status of 92 and 100%, respectively. More recently, the analysis of *KRAS*, *BRAF* and *PIK3CA* in tumour invasion fronts, lymph nodes and distant metastases revealed a discordance between primary tumours and lymph node metastases of 31, 4 and 13%, respectively (Baldus *et al*, 2010). A discordance between primary tumours and distant metastases was observed for *KRAS* in 10% of the cases and for *PIK3CA* in 5% of the cases (Baldus *et al*, 2010). In a large series of >800 samples tested for *KRAS*, using a highly sensitive SNaPshot-based method (Di Fiore *et al*, 2007), we observed a discordant *KRAS* mutational status between tumours and metastases in 10% of the paired samples (Lamy *et al*, 2010). These studies clearly indicate that given the genetic heterogeneity and genetic evolution of CRC under treatment, the most appropriate tissue on which molecular profiling should be performed remains to be determined.

CONCLUSION AND PERSPECTIVES

In conclusion, the numerous studies published since 2006 on the markers of sensitivity and resistance to anti-EGFR mAbs in MCRC have clearly validated somatic *KRAS* mutations as markers of resistance to anti-EGFR, resulting in restricted use of these targeted therapies to patients with no detectable *KRAS* mutation. However, in these patients, the heterogeneity of response strongly suggests that several genetic variations, corresponding either to somatic alterations present only within the tumours or to germline polymorphisms, can modulate sensitivity or resistance to anti-EGFR mAbs. One of the challenges is now to identify these other genetic predictive markers, using either candidate gene approaches, global analysis based on pangenomic/transcriptomic/proteomic portraits or cellular or animal models. Some technical and conceptual questions concerning *KRAS* genotyping remain unsolved. One important question under debate is to define in MCRC patients, the most appropriate tissue on which DNA

analysis should be performed in the context of targeted therapies. Indeed, most studies published so far are based on the analysis of genetic material extracted from primary tumours, whereas targeted therapies are mainly directed at metastatic disease treatment. As highlighted by several recent studies, this approach may have limitations: (1) the primary tumour may not always be available; (2) as indicated above, several genetic changes may occur between the primary tumour and the corresponding metastases; and (3) genetic analyses performed on paraffin-embedded tissues may generate artefacts because of fragmentation and chemical modification of DNA. Therefore, we think, as previously shown, that genetic analysis based on highly sensitive detection from blood of circulating mutant DNA might be of clinical interest (Di Fiore *et al*, 2008a; Yen *et al*, 2009).

As the new markers will have to be validated by independent studies, the challenge for the clinician, before treating patients, will be the progressive integration of these markers in the routine and

the development of a decisional algorithm, which should probably be stratified first by *KRAS* genotyping. In patients with *KRAS* mutations, the choice of the most appropriate treatment is problematic. Although the use of anti-EGFR mAbs is not recommended in these patients, it should be underlined that disease stability can be observed in up to 50% of chemorefractory patients treated with anti-EGFR alone in association with CT (Di Fiore *et al*, 2008b). In these patients, targeted therapies will probably be based, in the future, on molecules able to inhibit effectors of the EGFR transduction cascade and located downstream from the *KRAS* protein.

ACKNOWLEDGEMENTS

We are grateful to Pr Mario Tosi and Nikky Sabourin for the critical review of the manuscript.

REFERENCES

- Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lövig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N (2001) Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. *Br J Cancer* **85**: 692–696
- Amado GR, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type *KRAS* is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* **26**: 1626–1634
- Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, Lauricella C, Siena S (2008) Mutations of *KRAS* and *BRAF* in primary and matched metastatic sites of colorectal cancer. *J Clin Oncol* **26**: 4217–4219
- Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE (2010) Prevalence and heterogeneity of *KRAS*, *BRAF*, and *PIK3CA* mutations in primary colorectal adenocarcinomas and their corresponding metastases. *Clin Cancer Res* **16**: 790–799
- Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. *Cancer Res* **67**: 2643–2648
- Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F (2009) Impact of Fc[gamma]RIIIa-Fc[gamma]RIIIa polymorphisms and *KRAS* mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. *J Clin Oncol* **27**: 1122–1129
- Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* **27**: 663–671
- Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Schuch G, Zubel A, Celik I, Koralewski P (2010) Biomarkers predictive for outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX4 plus or minus cetuximab: Updated data from the OPUS study. Gastrointestinal Cancer Symposium, Abstract 428
- Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello C, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. *Ann Oncol* **19**: 717–723
- Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. *J Clin Oncol* **23**: 1803–1810
- Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. *N Engl J Med* **358**: 1160–1174
- Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. *Clin Cancer Res* **7**: 2958–2970
- Cohen SJ, Cohen RB, Meropol NJ (2005) Targeting signal transduction pathways in colorectal cancer – more than skin deep. *J Clin Oncol* **23**: 5374–5385
- Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* **351**: 337–345
- De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S (2008) *KRAS* wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. *Ann Oncol* **19**: 508–515
- Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboué R, Tuech JJ, Queuniet AM, Paillet B, Sabourin JC, Michot F, Michel P, Frébourg T (2007) Clinical relevance of *KRAS* mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. *Br J Cancer* **96**: 1166–1169
- Di Fiore F, Charbonnier F, Lefebvre B, Laurent M, Le Pessot F, Michel P, Frébourg T (2008a) Clinical interest of *KRAS* mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. *Br J Cancer* **99**: 551–552
- Di Fiore F, Van Cutsem E, Laurent-Puig P, Siena S, Frattini M, De Roock W, Lièvre A, Sartore-Bianchi A, Bardelli A, Tejpar S (2008b) Role of *KRAS* mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series. *J Clin Oncol* **26**(Suppl): Abstract 4035
- Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008) Wild-type *BRAF* is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J Clin Oncol* **26**: 5705–5712
- Douillard J, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel ME, Humblet Y, Cunningham D, Wolf M, Gansert JL (2009) Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. ECCO-ESMO LBA10. *Eur J Cancer Suppl*, **7**: 6
- Efeyan A, Serrano M (2007) P53: guardian of the genome and policeman of the oncogenes. *Cell Cycle* **6**: 1006–1010

- Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. *Br J Cancer* **97**: 1139–1145
- Garm Spindler KL, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF, Crüger D, Jakobsen A (2009) The importance of KRAS mutations and EGFR61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. *Ann Oncol* **20**: 879–884
- Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V, Bissoni R, Torresi U, Floriani I, Schiavon G, Andreoni F, Maltese P, Rulli E, Humar B, Falcone A, Giustini L, Tonini G, Fontana A, Masi G, Magnani M (2008) Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. *J Clin Oncol* **26**: 1427–1434
- Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer development. *Science* **319**: 1352–1355
- Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, Humblet Y, Penault-Llorca F, De Hertogh G, Laurent-Puig P, Van Cutsem E, Tejpar S (2009) Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. *J Clin Oncol* **27**: 5068–5074
- Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcborg JR, Dongsheng T, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebutt NC, Van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. *N Engl J Med* **357**: 2040–2048
- Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcborg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* **359**: 1757–1765
- Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto C, Godwin AK, Tan BR, Krishnamurthi SS, Burris III HA, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. *J Clin Oncol* **25**: 3230–3237
- Kim JS, Lee C, Bonifant C, Resson H, Waldman T (2007) Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. *Mol Cell Biol* **27**: 662–677
- Lamy A, Blanchard F, Le Pessot F, Houille S, Bossut J, Di Fiore F, Sesboué R, Sabourin JC (2010) Metastatic CRCs KRAS genotyping in routine diagnosis: Results and pitfalls. *ASCO GI Abstract* 294
- Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. *J Clin Oncol* **27**: 5924–5930
- Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. *Cancer Res* **66**: 3992–3995
- Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008) KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. *J Clin Oncol* **26**: 374–379
- Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A (2009b) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. *J Clin Oncol* **27**: 2622–2629
- Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F (2009a) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. *Br J Cancer* **101**: 715–721
- Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ (2008) Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. *Clin Cancer Res* **14**: 7884–7895
- Maughan T, Adams RA, Smith CG, Seymour MT, Wilson R, Meade AM, Fisher D, Madi A, Cheadle J, Kaplan R (2009) Addition of cetuximab to oxaliplatin-based combination chemotherapy in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). *ECCO-ESMO LBA6*. *Eur J Cancer Supp*, **7**: 4
- Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. *N Engl J Med* **352**: 476–487
- Molinari F, Martin V, Saletti P, De Dosso S, Spitale A, Camponovo A, Bordoni A, Crippa S, Mazzucchelli L, Frattini M (2009) Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. *Br J Cancer* **100**: 1087–1094
- Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. *Lancet Oncol* **6**: 279–286
- Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambilla E, Hainaut P (2007) Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. *Cancer Res* **67**: 5667–5672
- Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, Blanchard F, Tougeron D, Ychou Y, Boissière F, Le Pessot F, Sabourin JC, Tuech JJ, Michel P, Frebourg T (2009) TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. *Br J Cancer* **100**: 1330–1335
- Pander J, Gelderblom H, Antonini NF, Tol J, Krieken JH, Straaten TV, Punt CJ, Guchelaar HJ (2010) Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. *Eur J Cancer* **46**: 1829–1834
- Peeters M, Price T, Hotko Y, Cervantes A, Ducreux M, Andre T, Chan E, Lordick F, Rong A, Gansert J (2009) Randomized phase 3 study of panitumumab with FOLFIRI compared to FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). *ECCO-ESMO LBA14*. *Eur J Cancer Supp*, **7**: 9
- Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S (2009) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. *Ann Oncol* **20**: 84–90
- Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, Biesmans B, De Roock W, Capoen A, Debiec-Rychter M, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S (2008) Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. *Clin Cancer Res* **14**: 5869–5876
- Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S (2009) PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. *Clin Cancer Res* **15**: 3184–3188
- Razis E, Briassoulis E, Vrettou E, Skarlos DV, Papanicolaou D, Kostopoulos I, Samantas E, Xanthakis I, Bobos M, Galanidi E, Bai M, Gikonti I, Koukouma A, Kafiri G, Papakostas P, Kalogeras KT, Kosmidis P, Fountzilas G (2008) Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. *BMC Cancer* **8**: 234
- Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. *Cancer Res* **69**: 1851–1857
- Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, Berardi R, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S (2009) Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. *BMC Cancer* **9**: 303
- Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID (2010) Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. *Eur J Cancer* **46**: 1997–2009

- Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009a) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* **360**: 1408–1417
- Van Cutsem E, Lang I, Folprecht G, Nowacki M, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Celik I, Kohne C (2010) Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial. ASCO GI, Abstract 281
- Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care alone in patients with chemotherapy –refractory metastatic colorectal cancer. *J Clin Oncol* **25**: 1658–1664
- Van Cutsem E, Rougier P, Köhne C, Stroh C, Schlichting M, Bokemeyer C (2009b) A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients with metastatic colorectal (mCRC): results according to KRAS and BRAF mutations. ECCO-ESMO A6077. *Eur J Cancer Supp*, **7**: 345
- Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, Chang YT, Chu KS, Lin SR, Wang JY (2009) Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. *Clin Cancer Res* **15**: 4508–4513
- Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrad AE, Iqbal S, Groshen S, Lenz HJ (2007) FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. *J Clin Oncol* **25**: 3712–3718